The doctor recommended getting updated flu vaccines annually to lower the risk of contracting the virus and be protected from ...

Oxford University is hoping to create a vaccine to stop the disease 20 years before it develops, as part of a joint project with GSK to study pre-cancer biology ...

The output includes, in addition to the endpoint results (mismatch volumes and ratio) visualizations of segmented lesions in the context of the original data, details about the arterial input function ...

Some additional issues deserve to be addressed first, as several preventive public health measures have been taken worldwide, including Italy, to limit the spread of SARS-CoV-2, (i.e., hand hygiene ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...

Brand New Membership Level: Benzinga Trade Alerts GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...